FDA is examining the feasibility of requiring abuse-deterrence as a criterion for approving opioids or other abusable drugs.
“As we gain experience with both laboratory and real-world data concerning new opioid products formulated to deter abuse, we are actively considering whether, and under what circumstances, we can and...